Is Aurinia Pharmaceuticals, Inc. overvalued or undervalued?

As of 12 May 2025, the valuation grade for Aurinia Pharmaceuticals, Inc. has moved from attractive to fair. The company is currently fairly valued. Key ratios include a P/E ratio of 19, an EV to EBITDA of 11.23, and a PEG ratio of 0.10, indicating strong growth potential relative to its price.
In comparison to its peers, Aurinia's P/E ratio of 18.69 is more favorable than ANI Pharmaceuticals, Inc., which has a risky valuation with a P/E of -100.77. Additionally, Aurinia's EV to EBITDA is significantly lower than ANI's 24.22, suggesting a more efficient valuation relative to earnings before interest, taxes, depreciation, and amortization. Despite recent underperformance against the S&P 500, where Aurinia has seen a year-to-date decline of 12.81% compared to a 2.44% gain for the index, the company's strong ROCE of 99.51% and ROE of 16.33% highlight its operational efficiency.